Coherus Biosciences has notified the US markets authority that it will terminate a collaboration with Shanghai-based Junshi Biosciences related to an anti-TIGIT candidate. 11 January 2024
Rob Scott has been appointed chief medical officer (CMO) of Abionyx Pharma, a French biotech focused on the discovery and development of innovative therapies based on the world's only recombinant apoA-I. 10 January 2024
Blueprint Medicines Corporation has outlined its 2024 corporate strategy, promising accelerated revenue growth, sustainable research and development, and a clear path to profitability. 9 January 2024
UK pharma major GSK has entered into an agreement to acquire Anglo-American biotech Aiolos Bio, a clinical-stage company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions. 9 January 2024
Italian family-controlled drugmaker Chiesi Farmaceutici and Cambridge, USA-based Oak Hill Bio have executed a license and development agreement to develop, manufacture, and commercialize OHB-607. 9 January 2024
Breaking new ground, private Chinese start-up Argo Biopharmaceutical has won two exclusive license and collaboration contracts with Swiss cancer giant Novartis. 9 January 2024
US biopharma Applied Therapeutics has announced the top-line results of the ARISE-HF Phase III trial of AT-001 (caficrestat) in patients with diabetic cardiomyopathy (DbCM) at high risk of progression to overt heart failure. 8 January 2024
Shares of UK blood disease drug developer Hemogenyx Pharmaceuticals were down 7.5% at 2.13 pence as trading drew to a closed today, despite announcing the successful completion of its Process Qualification (PQ) run of the end-to-end process for the manufacture of HEMO-CAR-T cells. 8 January 2024
Kicking of the JP Morgan Healthcare conference this morning, Johnson & Johnson announced a definitive agreement to acquire Ambrx Biopharma. 8 January 2024
Swiss pharma giant Novartis has entered an agreement to acquire Dutch firm Calypso Biotech, a developer of Interleukin15 (IL-15) targeted therapies. 8 January 2024
Two Finnish companies, Orion Corporation and Glykos Finland Oy, have entered into a research collaboration and licensing agreement related to the development of antibody-drug conjugates (ADCs) to treat solid tumors. 8 January 2024
Paris, France-based cardiology specialist Corteria Pharmaceuticals has announced the appointment of Dr Mark Pruzanski, as chairman of its board of directors. 6 January 2024
Mersana Therapeutics today announced business updates, its expected milestones and its upcoming presentation at the 42nd Annual JP Morgan Healthcare Conference. 5 January 2024
Swiss pharma giant Roche has entered into a third licensing deal this week alone, signing an agreement with Cambridge, USA-based biotech MOMA Therapeutics. 5 January 2024
China and USA-based Allorion Therapeutics has announced a second licensing deal within a few days, this time entering an exclusive agreement with US clinical-state biotech Avenzo Therapeutics. 5 January 2024
US pharma major AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja's proprietary VivoVec platform. 5 January 2024
French rare disease company Innate Pharma has received good news from the US Food and Drug Administration, with a partial clinical hold being lifted from its lacutamab program. 5 January 2024
Dutch clinical-stage biotech NewAmsterdam Pharma yesterday provided an update on its clinical development programs and outlined its strategic priorities for 2024. 5 January 2024
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024